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     Trisomy 21 is the genetic source of the group of phenotypes commonly 
known as Down syndrome (DS). These phenotypes include cognitive im-
pairment, heart defects and craniofacial abnormalities, including a small 
mandible. The Ts65Dn mouse model contains three copies of approximately 
half the genes found on human chromosome 21 and exhibits similar pheno-
types to individuals with DS including a small, dysmorphic mandible. Our lab 
has traced this deficit to a smaller first branchial arch (BA1) consisting of 
fewer neural crest cells (NCCs) at embryonic day 9.5 (E9.5). At E9.5, 
Dyrk1a, a gene known to affect craniofacial development, is upregulated in 
the BA1, likely contributing to its cell deficit. Using epigallocatechin gallate 
(EGCG), an extract from green tea and a known inhibitor of Dyrk1a, we are 
attempting to rescue this deficit. We hypothesize the consumption of EGCG 
by pregnant mothers at E7 and E8 will rescue the mandibular deficit in de-
veloping embryos by reducing the expression or activity of Dyrk1a. From our 
data we conclude the treatment of pregnant mothers with EGCG results in 
increased embryo size of trisomic embryos. Further analysis will be done to 
determine embryo volume, the volume of the BA1, and number of NCCs 
within the BA1 to determine the effects of EGCG in vivo. This research will 
better our understanding of craniofacial development and could lead to po-
tential genetic-based therapies in the future. 
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